This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

Rybrevant (amivantamab) - originally developed by Danish biotech Genmab – has been cleared for NSCLC patients with exon 20 insertions ... Poziotinib targets both HER2 and EGFR, and will if ...

and exon 20 insertion mutations, and HER2 mutations in the kinase domains of exons 18, 19, 20, or 21. Patients with compound mutations or acquired resistance mutations in EGFR will also be included in ...

The duration of diabetes ranged from 1 to 20 ... HER2, Tumor Protein 53 (TP53), phosphoinositide 3-kinase (PIK3), and avian Erythroblastosis oncogene B 2 (ERBB2). Upon conducting univariate and ...

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Sunvozertinib received FDA priority review for NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy progression. The WU-KONG1 Part B study showed a 53.3% objective response ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC. Entered into clinical tr ...

Entrada Therapeutics announced it has been cleared in the U.K. to start a Phase 1/2 clinical trial of ENTR-601-44, at increasing doses, in Duchenne muscular dystrophy (DMD) patients with a mutation in ...